Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Pfizer's new 5-HT1 ligands useful for CNS and related disorders

Nov. 18, 1999

Angiotech commences phase II clinical study of micellar paclitaxel in SPMS

Nov. 18, 1999

Sumitomo's SM-13496: further clinical development may be handled overseas

Nov. 17, 1999

New benzamides for CNS disorders, particularly epilepsy, presented by SB

Nov. 17, 1999

Another series of dopamine agonists for schizophrenia, Parkinson's disease from AHP

Nov. 17, 1999

Long-acting local anesthetics bind to multiple sites on voltage-gated Na+ channels

Nov. 15, 1999

Agents that enhance serotonergic neurotransmission designed at Pfizer

Nov. 15, 1999

More on proteasome inhibitor PS-519, including chemical structure

Nov. 15, 1999

Mixed AMPA and glycine-site NMDA antagonist with i.v./i.p. anticonvulsant activity

Nov. 12, 1999

SUN-N5030 emerges as potent neuroprotectant from new class of dual Na+/Ca2+ channel blockers

Nov. 12, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...